Entrada Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Entrada reported Q2 2026 net loss of $42.8M (vs. $43.1M in Q2 2025) with cash position of $223.0M as of June 30, 2026 (down from $295.7M at year-end 2025). The company disclosed a catalyst-rich pipeline: ELEVATE-45-201 Cohort 1 data expected October 2026, ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, ELEVATE-44-201 Cohort 2 data in Q1 2027, and Vertex's VX-670 DM1 Phase 1/2 data in H2 2026. Cash runway extends into Q3 2027 based on current operating plans.
Why this rating
Multiple near-term clinical catalysts are meaningful for a ~$191M company, but no material business-changing events occurred. Cash burn ($72.7M in H1 2026) and runway adequacy are moderate concerns relative to company size.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.